Many Diplomat Pharmacy, Inc.(DPLO) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Diplomat Pharmacy Inc was Downgraded by Credit Suisse to Underperform on Nov 23, 2016.
Company has reported several Insider transactions to the SEC, on Sep 16, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 20,000 shares at 30.12 per share price.On Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at 33.60 per share price.On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at 35.08 per share price.
Diplomat Pharmacy Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.24. The company had revenue of $1181.00 million for the quarter, compared to analysts expectations of $1258.11 million. The companys revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS.
Diplomat Pharmacy, Inc. (NYSE:DPLO) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.64 by 11 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 9 Brokerage Firms have advised hold.
Diplomat Pharmacy, Inc. (NYSE:DPLO): 7 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $16.79 in Diplomat Pharmacy, Inc. (NYSE:DPLO). However, the stock price could fluctuate by $ 2.12 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $20 price target with the lower price estimate is calculated at $14
Diplomat Pharmacy, Inc. (NYSE:DPLO) rose 0.27% or 0.04 points on Tuesday and made its way into the gainers of the day. After trading began at $14.55 the stock was seen hitting $14.71 as a peak level and $14.4 as the lowest level. The stock ended up at $14.65. The daily volume was measured at 994,367 shares. The 52-week high of the share price is $38.94 and the 52-week low is $12.25. The company has a market cap of $978 million.
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.